drugset / Trial / NCT00380133

Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients

NCT00380133

Phase 1 Completed 20 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study will assess the effects of single oral doses of SB681323 and prednisolone on biomarkers in induced sputum and blood COPD patients

Timeline

Start
2005-06
Primary completion
2006-04
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisolone Other / unclassified 10 mg Oral
Subject Prednisolone Other / unclassified 30 mg Oral
Subject dilmapimod Small molecule 7.5 mg Oral
Subject dilmapimod Small molecule 25 mg Oral